STOCK TITAN
  1. Home
  2. KPHMW

KIORA PHARM WTS 9/27/27 (KPHMW) Stock Price, News & Analysis

KPHMW OTC
Published by Stock Titan Data refreshed

What Changed

Company Description

For FY2025, KIORA PHARM WTS 9/27/27 reported revenue of $0 with net income of -$10.8M and diluted earnings per share of -$2.64.

This page collects what Stock Titan holds for KPHMW, including price data, SEC filings, and financial highlights.

Stock Performance

Chart
$—
-
-
Last updated:
-
Performance 1 year
-
Market Cap
-
Shares outstanding

KPHMW Metrics & Rankings

Revenue
$0.0
#3,503
Piotroski F-Score
1/9
#7,289

Latest News

View All

No recent news available for KPHMW.

SEC Filings

View All

[4] 55,000 stock options granted to EVP at Kiora Pharmaceuticals (KPRX)

[3] Kiora Pharmaceuticals (KPRX) EVP listed with no stock

[SCHEDULE 13G] New investor crosses 5% ownership in Kiora Pharmaceuticals (NASDAQ: KPRX)

[8-K] Kiora Pharmaceuticals (KPRX) hires Keith Lane to lead clinical development

[8-K] Kiora (NASDAQ: KPRX) partners with CKD on KIO-301 for retinitis pigmentosa

[SCHEDULE 13G/A] ADAR1 group discloses 9.9% Kiora Pharmaceuticals (KPRX) stake via shares and warrants

[SCHEDULE 13G/A] Nantahala Capital discloses 9.99% Kiora Pharmaceuticals (KPRX) stake via 13G/A filing

[8-K] Kiora Pharmaceuticals (NASDAQ: KPRX) details Q2 loss and $24M financing

[10-Q] Kiora Pharmaceuticals (NASDAQ: KPRX) details Q2 2026 loss and cash runway

[4] Kiora (NASDAQ: KPRX) CFO uses 911 shares to cover tax obligations

KIORA PHARM WTS 9/27/27 has filed 10 recent SEC filings, including 3 Form 8-K, 2 Form 4, 2 Form SCHEDULE 13G/A, 1 Form 3. The most recent filing was submitted on September 18, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all KPHMW SEC filings →

Financial Highlights

View Full Financials

operating income reached -$12.8M, and net income was -$10.8M. Diluted earnings per share stood at -$2.64. The company generated -$10.0M in operating cash flow. The current ratio was 5.99, measuring current assets divided by current liabilities.

$0
Revenue (FY2025)
-$10.8M
Net Income (FY2025)
-$2.64
Diluted EPS (FY2025)
-$10.0M
Operating Cash Flow
5.99
Current Ratio
-$12.8M
Operating Income

Upcoming Events

Frequently Asked Questions

What is the revenue of KIORA PHARM WTS 9/27/27 (KPHMW) stock?

The FY2025 revenue of KIORA PHARM WTS 9/27/27 (KPHMW) is $0, from its most recent completed fiscal year.

What is the net income of KIORA PHARM WTS 9/27/27 (KPHMW)?

The FY2025 net income of KIORA PHARM WTS 9/27/27 (KPHMW) is -$10.8M, from its most recent completed fiscal year.

What is the earnings per share (EPS) of KIORA PHARM WTS 9/27/27 (KPHMW)?

The diluted earnings per share (EPS) of KIORA PHARM WTS 9/27/27 (KPHMW) is -$2.64 for FY2025, its most recent completed fiscal year. Learn more about EPS .

What is the operating cash flow of KIORA PHARM WTS 9/27/27 (KPHMW)?

The operating cash flow of KIORA PHARM WTS 9/27/27 (KPHMW) is -$10.0M for FY2025, its most recent completed fiscal year. Learn about cash flow.

What is the current ratio of KIORA PHARM WTS 9/27/27 (KPHMW)?

The current ratio of KIORA PHARM WTS 9/27/27 (KPHMW), current assets divided by current liabilities, was 5.99 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

What is the operating income of KIORA PHARM WTS 9/27/27 (KPHMW)?

The operating income of KIORA PHARM WTS 9/27/27 (KPHMW) is -$12.8M for FY2025, its most recent completed fiscal year. Learn about operating income.